Implementation of ERAS protocol in robot-assisted radical cystectomy with intracorporeal ileal conduit urinary diversion: An outcome analysis beyond the learning curve
Conclusions: While the initial outcomes of this combined treatment strategy appear promising in terms of complication rates and perioperative parameters, greater insight is required from multi-institutional data sets and prospective comparative studies to establish the true value of RARC + IIC and ERAS protocol for bladder cancer.
Authors: Goto T, Miyamoto H PMID: 32208041 [PubMed - as supplied by publisher]
This study thoroughly analyzed E-cadherin and associated changes in BC, and reports Ephrin-B1 as a new marker of tumor aggressiveness.
In conclusion, our study indicated that CRYAB, CGNL1, ECM1, and GPX3 are potential urine biomarkers of HGBC. These four novel urine biomarkers will have attractive applications to provide new diagnostic methods, prognostic predictors and treatment targets for HGBC, which could improve the prognosis of HGBC patients, if validated by further experiments and larger prospective clinical trials.
For mixed population of patients with non –muscle‐invasive bladder who were treated with and without Bacillus Calmette‐Guerin and without any immediate postoperative chemotherapy, we show that European Organisation for Research and Treatment of Cancer scale provides the best recurrence and progression prediction in comparison with Eur opean Association of Urology and Club Urologico Espanol de Tratamiento Oncologico risk scores. We highlight the role of diameter and tumor extent in transition prediction. AbstractBrief Description: The results demonstrate that the European Organisation for Research and Treatment of...
Biomarkers of carcinogens with a strong link to bladder cancer are present in urine of e-cigarette users, a systematic review suggests.Reuters Health Information
Condition: Rectal Cancer Intervention: Procedure: Empty Bladder planning CT scan and CBCTs Sponsor: Institut Cancerologie de l'Ouest Not yet recruiting
Abstract Interest in nanostructures such as titanate nanotubes (TNT) has grown notably in recent years due to their biocompatibility and economic viability, making them promising for application in the biomedical field. Quercetin (Qc) has shown great potential as a chemopreventive agent and has been widely studied for the treatment of diseases such as bladder cancer. Motivated by the possibilities of developing a new hybrid nanostructure with potential in biomedical applications, this study aimed to investigate the incorporation of quercetin in sodium (NaTNT) and zinc (ZnTNT) titanate nanotubes, and characterize t...
In this study, we analyzed the tumor tissues of 224 patients with pTa, pT1, and pT2 urinary bladder cancer. We performed a histomorphologic analysis and immunohistochemistry for p53, Ki-67, and E-cadherin, which were selected as markers of the malignant process. For pTa and pT1, univariate analyses of cancer-specific survival (CSS), progression-free survival (PFS), and recurrence-free survival (RFS) were calculated using the Kaplan-Meier method, the log-rank test and Cox regression. Multivariate analysis was performed by a Cox regression analysis. Ki-67 (P
We would like to thank van der Steen and colleagues for their comments on our recently published paper “Long-term Survival and Complications Following Bladder-Preserving Brachytherapy in Patients With cT1-T2 Bladder Cancer” . Undisputedly, the Arnhem group did extremely important pioneering work in the field of brachytherapy for bladder cancer, both open and robot-assisted. In our paper, we de scribed the long-term results achieved with both the open implantation as well as the robot-assisted laparoscopic approach (RAL), which do support the results previously published by van der Steen et al.
Abstract The immune system is important to control tumor development and progression. However, tumor cells and cells of the tumor microenvironment can induce immune escape mechanisms including activation of immune checkpoints such as PD-1/PD-L1. Based on this knowledge, new immune therapies including PD-1 and PD-L1 inhibition have been developed and are already recommended as standard treatment in metastatic bladder and kidney cancer patients. In addition to its role as a therapeutic target PD-L1 seems to be a prognostic parameter although data are controversial. Only little is known about signaling pathways induc...